NAMS
NewAmsterdam Pharma Co N.V.
$30.40
+0.46%
$3.6B
No data for this timeframe.
Vol
Market Cap$3.6B
Cap SizeMid Cap
Insider Activity0B / 10S
Insider Net $-$23.5M
SEC Reports1
Recent Activity
Jun 3, 2026
other
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
<p>NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Compa
May 26, 2026
Insider
Kooij Louise Frederika sold 65,000 shares
Chief Accounting Officer @ $35.69 ($2.3M)
May 26, 2026
Insider
Kooij Louise Frederika acquired via exercise 60,000 shares
Chief Accounting Officer @ $10.00 ($600.0K)
Apr 8, 2026
SEC
{
"summary": "NewAmsterdam Pharma issued a press release announcing participation in an upcoming investor conference,
PRESS-RELEASE — Impact 5/10
Mar 11, 2026
Insider
LANGE LOUIS G sold 44,173 shares
Director @ $30.41 ($1.3M)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$49.93 (Feb 2026)
Current $30.40
Low $37.36
Median $50.14
High $59.22
14 analysts
$37.36
$59.22
Analyst Ratings
9Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 19, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Feb 18, 2026 | Needham | MAINTAIN | Buy → Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Dec 16, 2025 | Stifel | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.42 ▲ +2.2% | $-0.49 — $-0.31 | -227% YoY | 12 |
| Next Q | $-0.42 ▲ +2.7% | $-0.49 — $-0.24 | 21% YoY | 12 |
| Current FY | $-1.58 ▲ +6.1% | $-1.83 — $-1.36 | -9% YoY | 12 |
| Next FY | $-1.32 ▲ +3.8% | $-2.72 — $2.21 | 15% YoY | 11 |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | Kooij Louise | SELL | $2.3M |
| May 26, 2026 | Kooij Louise | M | $600.0K |
| Mar 11, 2026 | LANGE LOUIS | SELL | $1.3M |
| Mar 9, 2026 | LANGE LOUIS | X | $0.00 |
| Mar 9, 2026 | LANGE LOUIS | X | $513.1K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
4 unique insiders with 20 transactions. Net insider value: -$23.5M ($0.00 bought, $23.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | Kooij Louise Frederika | Chief Accounting Officer | SELL | 65,000 | $35.69 | $2.3M |
| May 26, 2026 | Kooij Louise Frederika | Chief Accounting Officer | EXERCISE | 60,000 | $10.00 | $600.0K |
| Mar 11, 2026 | LANGE LOUIS G | Director | SELL | 44,173 | $30.41 | $1.3M |
| Mar 9, 2026 | LANGE LOUIS G | Director | EXERCISE | 44,619 | — | — |
| Mar 9, 2026 | LANGE LOUIS G | Director | EXERCISE | 44,619 | $11.50 | $513.1K |
| Mar 9, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | EXERCISE | 101,409 | — | — |
| Mar 9, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | SELL | 101,409 | $30.29 | $3.1M |
| Mar 6, 2026 | LANGE LOUIS G | Director | SELL | 28,186 | $29.41 | $829.0K |
| Mar 6, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | EXERCISE | 94,124 | — | — |
| Mar 6, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | SELL | 94,124 | $30.32 | $2.9M |
| Mar 5, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | EXERCISE | 104,467 | — | — |
| Mar 5, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | SELL | 104,467 | $30.30 | $3.2M |
| Mar 2, 2026 | Davidson Michael H. | Chief Executive Officer | EXERCISE | 443,707 | — | — |
| Feb 26, 2026 | Davidson Michael H. | Chief Executive Officer | EXERCISE | 183,332 | — | — |
| Feb 26, 2026 | Davidson Michael H. | Chief Executive Officer | SELL | 165,408 | $33.63 | $5.6M |
| Feb 25, 2026 | Davidson Michael H. | Chief Executive Officer | EXERCISE | 58,253 | — | — |
| Feb 25, 2026 | Davidson Michael H. | Chief Executive Officer | SELL | 46,517 | $35.11 | $1.6M |
| Feb 24, 2026 | Davidson Michael H. | Chief Executive Officer | EXERCISE | 64,708 | — | — |
| Feb 24, 2026 | Davidson Michael H. | Chief Executive Officer | SELL | 61,547 | $36.13 | $2.2M |
| Feb 20, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | SELL | 14,692 | $35.00 | $514.2K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 91% buy across 22 analysts — 9 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$49.93 mean target (Feb 2026)
$37.36 Low
$59.22 High
| Metric | Value |
|---|---|
| Current Price | $30.40 |
| Target Low | $37.36 |
| Target Mean | $49.93 |
| Target Median | $50.14 |
| Target High | $59.22 |
| # Analysts | 14 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.42 | $-0.49 | $-0.31 | -227.0% | +2.2% | 6↑ 3↓ | $0.0B | -92.0% | 12 |
| Next Q 2026-09-30 |
$-0.42 | $-0.49 | $-0.24 | 21.2% | +2.7% | 1↑ 0↓ | $0.0B | 2050.3% | 12 |
| Current FY 2026-12-31 |
$-1.58 | $-1.83 | $-1.36 | -8.9% | +6.1% | 8↑ 3↓ | $0.0B | 22.5% | 12 |
| Next FY 2027-12-31 |
$-1.32 | $-2.72 | $2.21 | 15.3% | +3.8% | 7↑ 2↓ | $0.1B | 466.0% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.421 | |
| 7d ago | $-0.431 | +0.009 |
| 30d ago | $-0.431 | +0.009 |
| 60d ago | $-0.435 | +0.013 |
| 90d ago | $-0.419 | -0.002 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 19, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Dec 16, 2025 | Stifel | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Jan 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
other
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
<p>NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Co
Jun 1, 2026
short_volume
Short Volume: NAMS — 69.1% short (0.3M / 0.5M)
Short: 349,516 | Exempt: 1,237 | TRF Vol: 505,982 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
<p>NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Com
May 12, 2026
short_interest
FTD: NAMS — 17,408 shares ($0.7M) failed to deliver
Settlement: 20260512, Price: $39.59, FTD Value: $689,182.72, NEWAMSTERDAM PHARMA CO NV SHS
May 11, 2026
other
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
<p>NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Com
May 7, 2026
earnings
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
<p align="center"><em>– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed</em><em>-</em><
May 7, 2026
earnings_calendar
NAMS Q1 2026 Earnings Before Market Open — 2026-05-07
May 7, 2026
short_volume
Short Volume: NAMS — 65.1% short (0.7M / 1.0M)
Short: 679,323 | Exempt: 3,000 | TRF Vol: 1,044,152 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
NAMS Q1 2026 Earnings Before Market Open — 2026-05-06
May 1, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Com
Apr 13, 2026
short_interest
FTD: NAMS — 46,415 shares ($1.6M) failed to deliver
Settlement: 20260413, Price: $34.76, FTD Value: $1,613,385.4, NEWAMSTERDAM PHARMA CO NV SHS
Apr 8, 2026
earnings
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
<p>NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “C
Apr 2, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “C
Mar 24, 2026
short_interest
FTD: NAMS — 22,139 shares ($0.7M) failed to deliver
Settlement: 20260324, Price: $30.01, FTD Value: $664,391.39, NEWAMSTERDAM PHARMA CO NV SHS
Mar 23, 2026
short_interest
FTD: NAMS — 66,235 shares ($1.9M) failed to deliver
Settlement: 20260323, Price: $28.94, FTD Value: $1,916,840.9, NEWAMSTERDAM PHARMA CO NV SHS